Home > Insider Trading > Filing (0001415889-24-025380)

Filing Details

Accession Number:: 0001415889-24-025380
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-10-17 17:05:20
Reporting Period:: 2024-10-15

Accepted Time:: 2024-10-17 17:05:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1736730	Camp4 Therapeutics Corp	CAMP	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1160077	L Marc Andreessen	C/O Andreessen Horowitz 2865 Sand Hill Road, Suite 101 Menlo Park CA 94025	No	No	Yes	No
1166586	A Benjamin Horowitz	C/O Andreessen Horowitz 2865 Sand Hill Road, Suite 101 Menlo Park CA 94025	No	No	Yes	No
1656626	Ah Equity Partners Bio I, L.l.c.	2865 Sand Hill Road, Suite 101 Menlo Park CA 94025	No	No	No	No
1656629	Ah Bio Fund I, L.p.	2865 Sand Hill Road, Suite 101 Menlo Park CA 94025	No	No	Yes	No
1889476	Ah Bio Fund Iv, L.p.	2865 Sand Hill Road, Suite 101 Menlo Park CA 94025	No	No	Yes	No
1889898	Ah Equity Partners Bio Iv, L.l.c.	2865 Sand Hill Road, Suite 101 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-10-15	1,398,067	$0.00	1,398,067	No	4	C	Indirect	By AH Bio Fund I, L.P., as nominee
Common Stock	Acquisiton	2024-10-15	181,818	$11.00	1,579,885	No	4	P	Indirect	By AH Bio Fund I, L.P., as nominee
Common Stock	Acquisiton	2024-10-15	545,454	$11.00	545,454	No	4	P	Indirect	By AH Bio Fund IV, L.P., as nominee

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By AH Bio Fund I, L.P., as nominee
No	4	P	Indirect	By AH Bio Fund I, L.P., as nominee
No	4	P	Indirect	By AH Bio Fund IV, L.P., as nominee

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Prime Preferred Stock	Disposition	2024-10-15	15,001,312	$0.00	1,337,513	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-10-15	679,163	$0.00	60,554	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
These shares are held of record by AH Bio Fund I, L.P. ("AH Bio I") for itself and as nominee for AH Bio Fund I-B, L.P. AH Equity Partners Bio I, L.L.C. ("AH EP Bio I"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaimsthe existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interesttherein, if any.
These shares are held of record by AH Bio Fund IV, L.P. ("AH Bio IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P., and CLF Partners III, LP (collectively, the "AH Bio Fund IV Entities"). AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV"), the general partner of AH Bio IV, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio IV, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio IV and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.